The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Fatty Liver Drugs Market Research Report 2025
Synopsis
Fatty liver drugs refer to medications or pharmaceutical treatments used in the management and treatment of fatty liver disease. Fatty liver disease, also known as hepatic steatosis, is a condition characterized by the accumulation of excess fat in the liver cells.
The global Fatty Liver Drugs market was valued at US$ 20140 million in 2023 and is anticipated to reach US$ 29870 million by 2030, witnessing a CAGR of 5.2% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Fatty Liver Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Fatty Liver Drugs.
Report Scope
The Fatty Liver Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Fatty Liver Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Fatty Liver Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Gilead Sciences
Astra Zenca
Immuron
Novartis
Takeda
Allergan
Intercept Pharmaceuticals
Conatus
Merk
Madrigal
Hepion Pharmaceuticals
Segment by Type
ALD
NAFLD
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Fatty Liver Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Fatty liver drugs refer to medications or pharmaceutical treatments used in the management and treatment of fatty liver disease. Fatty liver disease, also known as hepatic steatosis, is a condition characterized by the accumulation of excess fat in the liver cells.
The global Fatty Liver Drugs market was valued at US$ 20140 million in 2023 and is anticipated to reach US$ 29870 million by 2030, witnessing a CAGR of 5.2% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Fatty Liver Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Fatty Liver Drugs.
Report Scope
The Fatty Liver Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Fatty Liver Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Fatty Liver Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Gilead Sciences
Astra Zenca
Immuron
Novartis
Takeda
Allergan
Intercept Pharmaceuticals
Conatus
Merk
Madrigal
Hepion Pharmaceuticals
Segment by Type
ALD
NAFLD
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Fatty Liver Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Fatty Liver Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 ALD
1.2.3 NAFLD
1.3 Market by Application
1.3.1 Global Fatty Liver Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Fatty Liver Drugs Market Perspective (2019-2030)
2.2 Fatty Liver Drugs Growth Trends by Region
2.2.1 Global Fatty Liver Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Fatty Liver Drugs Historic Market Size by Region (2019-2024)
2.2.3 Fatty Liver Drugs Forecasted Market Size by Region (2025-2030)
2.3 Fatty Liver Drugs Market Dynamics
2.3.1 Fatty Liver Drugs Industry Trends
2.3.2 Fatty Liver Drugs Market Drivers
2.3.3 Fatty Liver Drugs Market Challenges
2.3.4 Fatty Liver Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Fatty Liver Drugs Players by Revenue
3.1.1 Global Top Fatty Liver Drugs Players by Revenue (2019-2024)
3.1.2 Global Fatty Liver Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Fatty Liver Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Fatty Liver Drugs Revenue
3.4 Global Fatty Liver Drugs Market Concentration Ratio
3.4.1 Global Fatty Liver Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Fatty Liver Drugs Revenue in 2023
3.5 Fatty Liver Drugs Key Players Head office and Area Served
3.6 Key Players Fatty Liver Drugs Product Solution and Service
3.7 Date of Enter into Fatty Liver Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Fatty Liver Drugs Breakdown Data by Type
4.1 Global Fatty Liver Drugs Historic Market Size by Type (2019-2024)
4.2 Global Fatty Liver Drugs Forecasted Market Size by Type (2025-2030)
5 Fatty Liver Drugs Breakdown Data by Application
5.1 Global Fatty Liver Drugs Historic Market Size by Application (2019-2024)
5.2 Global Fatty Liver Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Fatty Liver Drugs Market Size (2019-2030)
6.2 North America Fatty Liver Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Fatty Liver Drugs Market Size by Country (2019-2024)
6.4 North America Fatty Liver Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Fatty Liver Drugs Market Size (2019-2030)
7.2 Europe Fatty Liver Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Fatty Liver Drugs Market Size by Country (2019-2024)
7.4 Europe Fatty Liver Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Fatty Liver Drugs Market Size (2019-2030)
8.2 Asia-Pacific Fatty Liver Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Fatty Liver Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Fatty Liver Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Fatty Liver Drugs Market Size (2019-2030)
9.2 Latin America Fatty Liver Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Fatty Liver Drugs Market Size by Country (2019-2024)
9.4 Latin America Fatty Liver Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Fatty Liver Drugs Market Size (2019-2030)
10.2 Middle East & Africa Fatty Liver Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Fatty Liver Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Fatty Liver Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Fatty Liver Drugs Introduction
11.1.4 Pfizer Revenue in Fatty Liver Drugs Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Detail
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences Fatty Liver Drugs Introduction
11.2.4 Gilead Sciences Revenue in Fatty Liver Drugs Business (2019-2024)
11.2.5 Gilead Sciences Recent Development
11.3 Astra Zenca
11.3.1 Astra Zenca Company Detail
11.3.2 Astra Zenca Business Overview
11.3.3 Astra Zenca Fatty Liver Drugs Introduction
11.3.4 Astra Zenca Revenue in Fatty Liver Drugs Business (2019-2024)
11.3.5 Astra Zenca Recent Development
11.4 Immuron
11.4.1 Immuron Company Detail
11.4.2 Immuron Business Overview
11.4.3 Immuron Fatty Liver Drugs Introduction
11.4.4 Immuron Revenue in Fatty Liver Drugs Business (2019-2024)
11.4.5 Immuron Recent Development
11.5 Novartis
11.5.1 Novartis Company Detail
11.5.2 Novartis Business Overview
11.5.3 Novartis Fatty Liver Drugs Introduction
11.5.4 Novartis Revenue in Fatty Liver Drugs Business (2019-2024)
11.5.5 Novartis Recent Development
11.6 Takeda
11.6.1 Takeda Company Detail
11.6.2 Takeda Business Overview
11.6.3 Takeda Fatty Liver Drugs Introduction
11.6.4 Takeda Revenue in Fatty Liver Drugs Business (2019-2024)
11.6.5 Takeda Recent Development
11.7 Allergan
11.7.1 Allergan Company Detail
11.7.2 Allergan Business Overview
11.7.3 Allergan Fatty Liver Drugs Introduction
11.7.4 Allergan Revenue in Fatty Liver Drugs Business (2019-2024)
11.7.5 Allergan Recent Development
11.8 Intercept Pharmaceuticals
11.8.1 Intercept Pharmaceuticals Company Detail
11.8.2 Intercept Pharmaceuticals Business Overview
11.8.3 Intercept Pharmaceuticals Fatty Liver Drugs Introduction
11.8.4 Intercept Pharmaceuticals Revenue in Fatty Liver Drugs Business (2019-2024)
11.8.5 Intercept Pharmaceuticals Recent Development
11.9 Conatus
11.9.1 Conatus Company Detail
11.9.2 Conatus Business Overview
11.9.3 Conatus Fatty Liver Drugs Introduction
11.9.4 Conatus Revenue in Fatty Liver Drugs Business (2019-2024)
11.9.5 Conatus Recent Development
11.10 Merk
11.10.1 Merk Company Detail
11.10.2 Merk Business Overview
11.10.3 Merk Fatty Liver Drugs Introduction
11.10.4 Merk Revenue in Fatty Liver Drugs Business (2019-2024)
11.10.5 Merk Recent Development
11.11 Madrigal
11.11.1 Madrigal Company Detail
11.11.2 Madrigal Business Overview
11.11.3 Madrigal Fatty Liver Drugs Introduction
11.11.4 Madrigal Revenue in Fatty Liver Drugs Business (2019-2024)
11.11.5 Madrigal Recent Development
11.12 Hepion Pharmaceuticals
11.12.1 Hepion Pharmaceuticals Company Detail
11.12.2 Hepion Pharmaceuticals Business Overview
11.12.3 Hepion Pharmaceuticals Fatty Liver Drugs Introduction
11.12.4 Hepion Pharmaceuticals Revenue in Fatty Liver Drugs Business (2019-2024)
11.12.5 Hepion Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Fatty Liver Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of ALD
Table 3. Key Players of NAFLD
Table 4. Global Fatty Liver Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Fatty Liver Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Fatty Liver Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Fatty Liver Drugs Market Share by Region (2019-2024)
Table 8. Global Fatty Liver Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Fatty Liver Drugs Market Share by Region (2025-2030)
Table 10. Fatty Liver Drugs Market Trends
Table 11. Fatty Liver Drugs Market Drivers
Table 12. Fatty Liver Drugs Market Challenges
Table 13. Fatty Liver Drugs Market Restraints
Table 14. Global Fatty Liver Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Fatty Liver Drugs Market Share by Players (2019-2024)
Table 16. Global Top Fatty Liver Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Fatty Liver Drugs as of 2023)
Table 17. Ranking of Global Top Fatty Liver Drugs Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Fatty Liver Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Fatty Liver Drugs Product Solution and Service
Table 21. Date of Enter into Fatty Liver Drugs Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Fatty Liver Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Fatty Liver Drugs Revenue Market Share by Type (2019-2024)
Table 25. Global Fatty Liver Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Fatty Liver Drugs Revenue Market Share by Type (2025-2030)
Table 27. Global Fatty Liver Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Fatty Liver Drugs Revenue Market Share by Application (2019-2024)
Table 29. Global Fatty Liver Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Fatty Liver Drugs Revenue Market Share by Application (2025-2030)
Table 31. North America Fatty Liver Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Fatty Liver Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Fatty Liver Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Fatty Liver Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Fatty Liver Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Fatty Liver Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Fatty Liver Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Fatty Liver Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Fatty Liver Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Fatty Liver Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Fatty Liver Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Fatty Liver Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Fatty Liver Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Fatty Liver Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Fatty Liver Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 46. Pfizer Company Detail
Table 47. Pfizer Business Overview
Table 48. Pfizer Fatty Liver Drugs Product
Table 49. Pfizer Revenue in Fatty Liver Drugs Business (2019-2024) & (US$ Million)
Table 50. Pfizer Recent Development
Table 51. Gilead Sciences Company Detail
Table 52. Gilead Sciences Business Overview
Table 53. Gilead Sciences Fatty Liver Drugs Product
Table 54. Gilead Sciences Revenue in Fatty Liver Drugs Business (2019-2024) & (US$ Million)
Table 55. Gilead Sciences Recent Development
Table 56. Astra Zenca Company Detail
Table 57. Astra Zenca Business Overview
Table 58. Astra Zenca Fatty Liver Drugs Product
Table 59. Astra Zenca Revenue in Fatty Liver Drugs Business (2019-2024) & (US$ Million)
Table 60. Astra Zenca Recent Development
Table 61. Immuron Company Detail
Table 62. Immuron Business Overview
Table 63. Immuron Fatty Liver Drugs Product
Table 64. Immuron Revenue in Fatty Liver Drugs Business (2019-2024) & (US$ Million)
Table 65. Immuron Recent Development
Table 66. Novartis Company Detail
Table 67. Novartis Business Overview
Table 68. Novartis Fatty Liver Drugs Product
Table 69. Novartis Revenue in Fatty Liver Drugs Business (2019-2024) & (US$ Million)
Table 70. Novartis Recent Development
Table 71. Takeda Company Detail
Table 72. Takeda Business Overview
Table 73. Takeda Fatty Liver Drugs Product
Table 74. Takeda Revenue in Fatty Liver Drugs Business (2019-2024) & (US$ Million)
Table 75. Takeda Recent Development
Table 76. Allergan Company Detail
Table 77. Allergan Business Overview
Table 78. Allergan Fatty Liver Drugs Product
Table 79. Allergan Revenue in Fatty Liver Drugs Business (2019-2024) & (US$ Million)
Table 80. Allergan Recent Development
Table 81. Intercept Pharmaceuticals Company Detail
Table 82. Intercept Pharmaceuticals Business Overview
Table 83. Intercept Pharmaceuticals Fatty Liver Drugs Product
Table 84. Intercept Pharmaceuticals Revenue in Fatty Liver Drugs Business (2019-2024) & (US$ Million)
Table 85. Intercept Pharmaceuticals Recent Development
Table 86. Conatus Company Detail
Table 87. Conatus Business Overview
Table 88. Conatus Fatty Liver Drugs Product
Table 89. Conatus Revenue in Fatty Liver Drugs Business (2019-2024) & (US$ Million)
Table 90. Conatus Recent Development
Table 91. Merk Company Detail
Table 92. Merk Business Overview
Table 93. Merk Fatty Liver Drugs Product
Table 94. Merk Revenue in Fatty Liver Drugs Business (2019-2024) & (US$ Million)
Table 95. Merk Recent Development
Table 96. Madrigal Company Detail
Table 97. Madrigal Business Overview
Table 98. Madrigal Fatty Liver Drugs Product
Table 99. Madrigal Revenue in Fatty Liver Drugs Business (2019-2024) & (US$ Million)
Table 100. Madrigal Recent Development
Table 101. Hepion Pharmaceuticals Company Detail
Table 102. Hepion Pharmaceuticals Business Overview
Table 103. Hepion Pharmaceuticals Fatty Liver Drugs Product
Table 104. Hepion Pharmaceuticals Revenue in Fatty Liver Drugs Business (2019-2024) & (US$ Million)
Table 105. Hepion Pharmaceuticals Recent Development
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Fatty Liver Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Fatty Liver Drugs Market Share by Type: 2023 VS 2030
Figure 3. ALD Features
Figure 4. NAFLD Features
Figure 5. Global Fatty Liver Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Fatty Liver Drugs Market Share by Application: 2023 VS 2030
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Others Case Studies
Figure 10. Fatty Liver Drugs Report Years Considered
Figure 11. Global Fatty Liver Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Fatty Liver Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Fatty Liver Drugs Market Share by Region: 2023 VS 2030
Figure 14. Global Fatty Liver Drugs Market Share by Players in 2023
Figure 15. Global Top Fatty Liver Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Fatty Liver Drugs as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Fatty Liver Drugs Revenue in 2023
Figure 17. North America Fatty Liver Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Fatty Liver Drugs Market Share by Country (2019-2030)
Figure 19. United States Fatty Liver Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Canada Fatty Liver Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Fatty Liver Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Fatty Liver Drugs Market Share by Country (2019-2030)
Figure 23. Germany Fatty Liver Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. France Fatty Liver Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. U.K. Fatty Liver Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Italy Fatty Liver Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Russia Fatty Liver Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Nordic Countries Fatty Liver Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Fatty Liver Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Fatty Liver Drugs Market Share by Region (2019-2030)
Figure 31. China Fatty Liver Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Japan Fatty Liver Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. South Korea Fatty Liver Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Southeast Asia Fatty Liver Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. India Fatty Liver Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Australia Fatty Liver Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Fatty Liver Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Fatty Liver Drugs Market Share by Country (2019-2030)
Figure 39. Mexico Fatty Liver Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Brazil Fatty Liver Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Fatty Liver Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Fatty Liver Drugs Market Share by Country (2019-2030)
Figure 43. Turkey Fatty Liver Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Saudi Arabia Fatty Liver Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Pfizer Revenue Growth Rate in Fatty Liver Drugs Business (2019-2024)
Figure 46. Gilead Sciences Revenue Growth Rate in Fatty Liver Drugs Business (2019-2024)
Figure 47. Astra Zenca Revenue Growth Rate in Fatty Liver Drugs Business (2019-2024)
Figure 48. Immuron Revenue Growth Rate in Fatty Liver Drugs Business (2019-2024)
Figure 49. Novartis Revenue Growth Rate in Fatty Liver Drugs Business (2019-2024)
Figure 50. Takeda Revenue Growth Rate in Fatty Liver Drugs Business (2019-2024)
Figure 51. Allergan Revenue Growth Rate in Fatty Liver Drugs Business (2019-2024)
Figure 52. Intercept Pharmaceuticals Revenue Growth Rate in Fatty Liver Drugs Business (2019-2024)
Figure 53. Conatus Revenue Growth Rate in Fatty Liver Drugs Business (2019-2024)
Figure 54. Merk Revenue Growth Rate in Fatty Liver Drugs Business (2019-2024)
Figure 55. Madrigal Revenue Growth Rate in Fatty Liver Drugs Business (2019-2024)
Figure 56. Hepion Pharmaceuticals Revenue Growth Rate in Fatty Liver Drugs Business (2019-2024)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
